New opportunities to optimize antithrombotic therapy for secondary stroke prevention

被引:5
|
作者
Kim, Anthony S. [1 ]
Easton, J. Donald [1 ]
机构
[1] UCSF, Dept Neurol, San Francisco, CA USA
关键词
Stroke prevention; secondary stroke prevention; antithrombotic; antiplatelet; clopidogrel; ticagrelor; aspirin; transient ischemic attack; MINOR STROKE; ASPIRIN; CLOPIDOGREL;
D O I
10.1177/1747493019828548
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for symptomatic carotid artery stenosis, anticoagulation for atrial fibrillation, high-dose statins, new oral anticoagulants, new developments in atrial fibrillation detection, and new therapeutics are in development. For antiplatelet therapy, aspirin monotherapy is effective but dual antiplatelet therapy with the combination of aspirin and clopidogrel increases hemorrhage risks over the long term that outweigh potential benefits. In the short term though, both the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a benefit of short-term dual-antiplatelet therapy, though the increased major hemorrhage risk seen in POINT could justify applying dual-antiplatelet therapy to just the first 21 days. Furthermore, since clopidogrel is a prodrug that must be metabolized to have antiplatelet activity, it is not surprising that the treatment effect in CHANCE was limited to patients who were not carriers of loss-of-function alleles for clopidogrel metabolism. Ticagrelor, an antiplatelet agent which failed to meet its primary endpoint as monotherapy compared to aspirin in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, is currently being tested as combination therapy with aspirin compared to aspirin alone in Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES). These developments along with improvements to the infrastructure to perform rapid evaluations and to apply intensive secondary stroke prevention interventions hold continued promise for the future.
引用
收藏
页码:220 / 222
页数:3
相关论文
共 50 条
  • [11] UPDATE ON ANTITHROMBOTIC AGENTS IN SECONDARY STROKE PREVENTION
    Rundek, Tatjana
    Basic-Kes, Vanja
    Morovic, Sandra
    Demarin, Vida
    ACTA CLINICA CROATICA, 2011, 50 (01) : 101 - 106
  • [12] Update on antithrombotic secondary prevention of ischemic stroke
    Koehrmann, Martin
    Kleinschnitz, Christoph
    NERVENARZT, 2019, 90 (10): : 995 - 1004
  • [13] Hemorrhagic transformation and stroke recurrence in children with cardiac disease receiving antithrombotic therapy for secondary stroke prevention
    Pulcine, Elizabeth
    Seed, Mike
    Brandao, Leonardo R.
    Slim, Mahmoud
    Palasamudram, Sunitha
    Shroff, Manohar
    Moharir, Mahendranath
    deVeber, Gabrielle
    Dlamini, Nomazulu
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (10) : 2428 - 2439
  • [14] Antithrombotic therapy for stroke prevention in atrial fibrillation
    Go, AS
    Fang, MC
    Singer, DE
    PROGRESS IN CARDIOVASCULAR DISEASES, 2005, 48 (02) : 108 - 124
  • [15] Antithrombotic therapy for prevention and treatment of ischemic stroke
    Albers, GW
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2001, 12 (01) : 19 - 22
  • [16] Prescription and adherence patterns of antithrombotic therapy for the secondary prevention of stroke in patients with atrial fibrillation
    Sanchez-Saez, Francisco
    Riera-Arnau, Judit
    Hurtado-Navarro, Isabel
    Rodriguez-Bernal, Clara
    Sanfelix-Gimeno, Gabriel
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 21 - 21
  • [17] Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
    Lin, Yi-Pin
    Tan, Teng-Yeow
    MEDICINE, 2015, 94 (38)
  • [18] Antithrombotic Therapy in Stroke Prevention and Treatment: A Review
    Marilyn M. Rymer
    Journal of Thrombosis and Thrombolysis, 1998, 5 (Suppl 1) : 43 - 47
  • [19] Antithrombotic Therapy for Prevention and Treatment of Ischemic Stroke
    Gregory W. Albers
    Journal of Thrombosis and Thrombolysis, 2001, 12 : 19 - 22
  • [20] Oral antithrombotic therapy in primary and secondary prevention
    Möllmann, H
    Elsässer, A
    Hamm, CW
    HERZ, 2005, 30 (03) : 181 - 184